TheraRadar
Clinical-Stage Companies / Mirror Biologics

Mirror Biologics

Pre-Approval PRO BETA
15
Total Trials
2
Phase 3
15
Phase 2
0
Recruiting
176
Score

Pipeline by Phase

Phase 3
2
Phase 2
15
Phase 1
7

Therapeutic Focus

Hepatocellular Carcinoma Metastatic Colorectal Cancer Colorectal Cancer Metastatic Virus Diseases Pneumonia

Clinical Trials (15)

NCT05033522 Phase 2 SUSPENDED

Immunotherapy for Advanced Liver Cancer

Started: 8/1/2023

NCT06557278 Phase 2 WITHDRAWN

Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer

Started: 11/1/2026

NCT04444622 Phase 2 COMPLETED

Immunotherapy for Third Line Metastatic Colorectal Cancer

Started: 7/12/2021

NCT02380443 Phase 2 COMPLETED

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

Started: 9/1/2016

NCT01998542 Phase 2 COMPLETED

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck

Started: 1/1/2016

NCT02624999 Phase 2 WITHDRAWN

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

Started: 12/1/2016

NCT01741038 Phase 2 WITHDRAWN

AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer

Started: 12/1/2017

NCT02409524 Phase 2 COMPLETED

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

Started: 7/1/2016

NCT04441047 Phase 1 COMPLETED

Universal Anti-Viral Vaccine for Healthy Elderly Adults

Started: 7/12/2021

NCT02018419 Phase 1 WITHDRAWN

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

Started: 3/1/2014

NCT00558675 Phase 1 COMPLETED

A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

Started: 12/1/2010

NCT01995227 Phase 1 WITHDRAWN

An Individualized Anti-Cancer Vaccine Study in Patients With HCC

Started: 12/1/2013

NCT00861965 Phase 1 TERMINATED

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Started: 1/1/2010

NCT01923233 Phase 1 WITHDRAWN

In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer

Started: 11/1/2014

NCT00861107 Phase 1 COMPLETED

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

Started: 8/1/2009

Drug Candidates

AlloStim® immunotherapy FOLFOX regimen Sorafenib Lenvatinib AlloStim Bavencio AlloVax CRCL AlloVax™ Cisplatin
Activity Status: Active
Last Trial Started: 11/1/2026
Last Trial Ended: 3/31/2025
Trials (12 months): 1
Completed Trials: 7
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.